Reporting Form for Adverse Events Following Immunization

The attached Adverse Event Following Immunization Form developed by Alberta Health (AH) is for use by Alberta Immunization Providers. Immunizers should follow processes specific to each zone for AEFI reporting and follow-up.

The attached form can be found on the AH website at the following web link: http://www.health.alberta.ca/professionals/immunization-policy.html

Zone Contact Information for AEFI:

The following is contact information for questions related to the reporting and follow-up of AEFI for any provincially funded vaccines or vaccine purchased by AHS Public Health Programs.

North Zone:

CDC Intake

Fax: 1-855-532-4373 Phone: 1-855-513-7530

Edmonton Zone:

Immunization Team Fax: 780-342-0248 Phone: 780-342-0229

Central Zone:

Communicable Disease Control

Fax: 403-356-2053 Phone: 403-356-6420

Calgary Zone:

Communicable Disease Unit

Fax: 403-955-6755 Phone: 403-955-6750

South Zone:

Public Health Nursing Team

Fax: 403-380-2893 Phone: 403-388-6684

AEFI Form Instructions for Use:

1. Demographic Information:

Complete ALL demographic information.

- a. RHA (Regional Health Authority) Number the number of the Zone submitting the report.
 - North: Zone 5
 Edmonton: Zone 4
 Central: Zone 3
 Calgary: Zone 2
 South: Zone 1
- b. <u>Delivery Management Site</u> the name or number of the Public Health Centre/Unit submitting the report
- c. Report Date date on which the form is completed.
- d. <u>LIN Number</u> an IMPACT Local Inventory Number (LIN) is to be assigned by the IMPACT Nurse monitor when an AEFI report is generated from an IMPACT centre. The IMPACT LIN is used to link the initial provincial/territorial AEFI report to the IMPACT report. Once both reports have been received, the data contained on the AEFI form and the IMPACT forms are merged in the CAEFISS database.
- e. Parent/Guardian Names ensure names are current.
- 2. Medical History: Check appropriate boxes.

3. Immunization Information:

a. <u>Date of Immunization</u> - date that the vaccine (s) temporally related to the adverse event was/were given.

List **all** vaccines given on the day identified as the date of immunization.

- Information for a maximum of 5 immunizing agents administered on the same visit can be included on the form.
- In the rare event that 6 or more agents are administered, the additional information is to be included on a separate page(s) using progress notes and attached to the AEFI form.
- Number the attached page(s), numbering the first attached page as "page 2".
- Ensure that the client's name and birth date are at the top of the additional sheet
- Do NOT add another AEFI form.
- b. <u>Time of Immunization</u> time that the vaccine(s) temporally related to the adverse event was/were given
- c. <u>Vaccine Code</u> located in the specific AHS vaccine biological page. Do not use trade names (e.g., Infanrix- IPV- Hib).
- d. <u>Manufacturer</u> enter the manufacturer's name for each of the immunizing agents. Manufacturer is listed in the specific AHS vaccine biological page
- e. <u>Lot Number</u> record lot number as it appears on the vaccine box, vial, ampoule or preloaded syringe.
- f. No. in Series enter the actual number of the dose given. (i.e., 1, 5, 8).
 - Do not use the term booster when describing the dose number (e.g., MMR-Var after MMR is dose 2).
 - If number in series is unknown, leave the space blank
- g. <u>Dosage</u> use "**mL**", not 'cc' when recording the dose of the immunizing agent.
- h. Route use the following abbreviations to describe route of administration:

ID	Intradermal	IM	Intramuscular
РО	Oral	SC	Subcutaneous
IN	Intranasal		

i. <u>Site</u> - use the following abbreviations to describe site:

R	Right	L	Left
Α	Arm	L	Leg
G	Gluteal	MO	Mouth
MS	Multiple sites	NO	Nose
U*	Upper	L*	Lower
F*	Forearm		

e.g., to indicate that the right arm was used, enter RA

If the site used is not listed, state reason in the "Description of Event" section.

*Dependent on selections available in the electronic systems. Should be included in paper forms when used.

4. Reportable Adverse Events:

- Report all serious and unexpected events following immunization that meet the criteria for each category as listed in the AH Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers.
- Report the onset interval and the duration for each specific event reported. The onset and duration intervals are to be reported in minutes (M), hours (H) or days (D)
 E.g., fever (#1) of 39 °C started 8 hours after immunization and resolved within 48 hours, convulsion/seizure (#9) started 12 hours after immunization and resolved within 24 hours. You would enter information as follows:

	Adverse Event		Onset	•	Duration			
Adverse Event		M	Н	D	M	Н	D	
1	Fever <u>39</u> C⁰		8			48		
9	Convulsions/Seizures		12			24		

c. For those categories requiring diagnosis by a physician, attach supporting documentation such as laboratory reports, summary notes, etc.

5. Description of Event:

Provide specific information that is not captured by the categories in this section. Information should apply to the reaction ONLY.

- Documentation of attempted phone calls, conversations with the client, etc. should be included in the progress notes on the client's file but are **not** to be included with the AEFI report.
- If a physician was consulted or the client was seen in ER or hospitalized, please provide the full name of same.
- If the space is insufficient, attach a separate page (progress notes). Do not add another adverse events following immunization form.
 - Ensure that the client's name and birth date are at the top of the additional sheet and number the pages
- Do not use days of the week but actual dates (e.g., October 23)

6. Level of Care Received:

Check appropriate boxes. If hospitalized complete date of admission and discharge.

7. Treatment:

Check appropriate box. If treatment received, check appropriate boxes.

8. Outcome of Events:

Check appropriate box. If final outcome is expected within a 2 week interval, keep AEFI report until this information is available, e.g., local reactions. If outcome is still pending at 2 weeks following initial report, submit the original report and send an update when final outcome is known. If unable to contact client to complete AEFI submit with outcome of "Lost to follow up".

9. Reporter Name:

- Print the initial and surname of the person completing/submitting the AEFI form.
- Check designation.
- Sign name and provide phone number

10. Regional Recommendations and Comments:

This section will be completed as per zone process.



Report of Adverse Events Following Immunization

☐ Initial Report ☐ Up	dated Rep	ort	Shadeo	areas	are no	t reporte	d electronic	cally.	EFI#	For	Albert	a Hea	lth (Only
RHA Number (Reporting RHA)		y Manage				onal Health		Report Date				Numbe		15
Client Name (Last)	(First)			(Middle)			Gender Male	Female [Unki	nown	Date of	Birth (y	ууу-тп	n-dd)
Client Address							Parent/Guar		Marin .					
City			Province	е		_		Postal C	Code	P	hone Nur	nber		
Medical History:						_								
Current Medications: Yes	□ No □	Unknown	If yes	specify:										
Known Medical Conditions:					ecify:									
History of allergies: Yes														
Previous Adverse Event to Imm History of Convulsions:		Yes [yes specif	y:							
Immunization Information				- 17		tion (yyyy-n	nm-dd):		Time	e of Im	munizati	on:		350
Vaccine Code	Manufact	urer	Lot # No. in Series			Dosage		Route			Site			
			-		-			-						_
Adverse Event		Onse		Dura	tion		Advorso	Fuent		(Onset		Duratio	on
1 Fever C°		м н	D	M H		27 🗆 Arti	Adverse ralgia/Arthriti		eation)	М	H D		Н	D
2 Infective Abscess (attach	lab results)		\vdash	_	+		vere Diarrhea			-		+	-	+
Pain and/or Swelling					1	29 Par						+	\vdash	\vdash
Screaming Episode/Persis	stent Crying				1	30 🗆 Ord	hitis*					+	\vdash	\vdash
Convulsions/Seizures						31Thr	ombocytopen	ia*(attach lab	results)					\vdash
2 Anaesthesia/paraesthesia						33 Cel	lulitis*							П
3 ☐ Paralysis*						34 Ste	rile Abscess							
4 ☐ Guillain-Barré Syndrome*						35 No	3330731.							
5 Subacute Sclerosing Pane (SSPE)*	encephalitis					36 End	ephalitis, ADI	EM, Myelitis*						Г
6 Adenopathy (provide loca	tion)			\neg	+	37 ☐ Me	ningitis*				-	+-	\vdash	\vdash
7 Anaphylaxis							ulo-Respirator	y Syndrome	(ORS)					
8 Allergic Reaction (provide	description)					39 Bel	's Palsy*							\Box
20 Erythema Multiforme*						40 Intu	ssusception*							
21 Rash (provide description					_	32 Oth	er Unusual E	vents				_		
22 Hypotonic Hyporesponsiv	e Episode	-	\vdash	_	+	* Must b	e diagnosed	hv a nhvsici	an Plea	iso Pr	nvide De	taile		
Description of Event:							- and	-, - p.,, c.c.	,		01100 00	tuno		
						+								_
	-					+								_
													_	
		-				-								
Level of Care Received			T	reatme	nt				Outcor	ne of	Events			
Advice from a Health Profes		Yes No U						Clie	nt fully	recovere	ed			
Emergency room		If yes, indicate type of tre Analgesic/Antipyretic									y/incap	acity		
Required Hospitalization		Yes No U				nknown		Dea	th					
Admission Date (yyyy-mm-d		Epinephrine						Lost						
Discharge Date (yyyy-mm-d	d):		Yes No U				Inknown Not yet recovered Unknown							
			Antihistamine Yes No U				nknown		Unk	nown				
				Other (s										
Reporter Name:						Signature	:				Pho	ne Nun	ber:	
Reporter Designation: RN		.PN _N	P DP	HARM [ОТН									
Regional Recommendation Change to immunization scheme		CMOH A	tuico D	auactad		No further	immunization	Cassifu						
Expert Referral (specify typ		CMOHA	wice Re	equesteo	П	Other	immunization. (specify):	. Specify:						
Comments	-				_									_
						-						4		_
												_		
Print Name (MOH/Designate):			Sig	nature:					hone Nu	2000				
D0808 (2014/01) Enhar	nced reportin	g form att	ached					D	ate Rep	oned ((уууу-тт-		Page	1 of
C C C C C C C C C C C C C C C C C C C		o .o.m att	-01100										Page	1 01